Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test

Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.

MT1801_Lung Cancer_47781766_1200

More from Oncology

More from Device Area